Oxytocin for frontotemporal dementia

Finger, Elizabeth; MacKinley, Julia; Blair, Mervin; Oliver, Lindsay D.; Jesso, Sarah; Tartaglia, Maria Carmela; Borrie, Michael; Wells, Jennie; Dziobek, Isabel; Pasternak, Stephen; Mitchell, Derek; Rankin, Katherine P.; Kertesz, Andrew; Boxer, Adam L.

doi:10.1212/wnl.0000000000001133

Cited by 86 publications

(78 citation statements)

References 25 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Oxytocin through interactions with gonadal hormones has also been suggested to affect sexual function [45], with decreased levels or action potentially producing decreased sexual drive. When bvFTD patients are administered oxytocin a proportion develop hypersexual behavior [46]. As such, it is possible that neuroendocrine abnormalities modulate hyposexual behavior, and this proposal requires further investigation.…”

Section: Discussionmentioning

confidence: 99%

Characterizing Sexual Behavior in Frontotemporal Dementia

Kaizik

Irish

Mioshi

et al. 2015

JAD

View full text Add to dashboard Cite

Abstract.Background: Frontotemporal dementia (FTD) is characterized by a number of prominent behavioral changes. While FTD has been associated with the presence of aberrant or unusual sexual behaviors in a proportion of patients, few studies have formally investigated changes in sexual function in this disease. Objective: We aimed to systematically quantify changes in sexual behavior, including current symptoms and changes from prior diagnoses, in behavioral-variant (bvFTD) and semantic dementia (SD), compared to Alzheimer's disease (AD). Methods: Carers of 49 dementia patients (21 bvFTD, 11 SD, 17 AD) were interviewed using the Sexual Behavior and Intimacy Questionnaire (SIQ), a survey designed to assess changes in sexual function across multiple domains including initiating, level of affection, and aberrant or unusual sexual behavior. Results: BvFTD patients show prominent hyposexual behavior including decreased affection, initiation, and response to advances by partners, and decreased frequency of sexual relations, compared to AD and to SD patients. The greatest changes in sexual behavior compared to pre-diagnoses were found in the bvFTD group with a 90-100% decrease in initiation, response, and frequency of sexual relations. Notably, aberrant or unusual sexual behavior was reported in a minority of bvFTD and SD patients and occurred in patients who also showed hyposexual behavior toward their partner. Conclusion: Overall loss of affection, reduced initiation of sexual activity, and responsiveness is an overwhelming feature of bvFTD. In contrast, aberrant or unusual sexual behavior is observed in the minority of bvFTD patients. The underlying pathophysiology of these changes likely reflects structural and functional changes in frontoinsular and limbic regions including the hypothalamus.

show abstract

Section: Discussionmentioning

confidence: 99%

Characterizing Sexual Behavior in Frontotemporal Dementia

Kaizik

Irish

Mioshi

et al. 2015

JAD

View full text Add to dashboard Cite

show abstract

“…Of note, other novel approaches to managing behavioral symptoms for FTD are currently being studied in placebocontrolled trials. The neuropeptide oxytocin, an important mediator of social behavior, was administered intranasally to 20 bvFTD and three svPPA patients in a double-blind, randomized, placebo-controlled, crossover trial over 1 week and demonstrated possible trend toward improved apathy and empathy (Finger et al 2015).…”

Section: Behavioral Symptoms Managementmentioning

confidence: 99%

Therapy and clinical trials in frontotemporal dementia: past, present, and future

Tsai

Boxer

2016

Journal of Neurochemistry

126

View full text Add to dashboard Cite

Frontotemporal dementia (FTD) is a common form of dementia with heterogeneous clinical presentations and distinct clinical syndromes. This article will review currently available therapies for FTD, its related disorders and their clinical evidence. It will also discuss recent advancements in FTD pathophysiology, treatment development, biomarker advancement and their relation to recently completed or currently ongoing clinical trials as well as future implications.

show abstract

“…The study by Finger and colleagues did not report significance for measures given the small sample size [Finger et al 2015]. Trends were found in improvements on the NPI, FBI, and the Interpersonal Reactivity Index (IRI) in the oxytocin group.…”

Section: Resultsmentioning

confidence: 95%

“…This systematic review of the literature only identified two RCTs that evaluated the use of oxytocin in individuals with FTD [Jesso et al 2011;Finger et al 2015]. Both studies were of good quality based on the criteria developed by the Center for Evidence Based Medicine [CEBM, 2014].…”

Section: Resultsmentioning

confidence: 99%